Critical Care Therapeutics Market Size , Share , Trends , Analysis and Forecasts To 2021
Market Research analysts forecast the global critical care therapeutics market to grow at a CAGR of 3.62 % during the period 2017-2021 .
The following companies as the key players in the global critical care therapeutics market : CSL Behring , Grifols , Kedrion Biopharma , Octapharma , and Shire .
Other Prominent Vendors in the market are : Abeona Therapeutics , ADMA Biologics , Albumedix , Armetheon , Asklepios BioPharmaceutical , Aspen Pharma , Baxter , Bayer HealthCare , Bio Products Laboratory , BioDelivery Sciences , Biogen Idec , BioMarin , Biotest Pharmaceuticals , Bristol-Myers Squibb , Catalyst Biosciences , China Biologic Products , Cosmo Pharmaceuticals , Kamada , King Pharmaceuticals , Medxbio , Merck , Mitsubishi Tanabe Pharma , Novo Nordisk , Novozymes , Portola Pharmaceuticals , ProMetic Life Sciences , rEVO Biologics , Rockwell Medical , Sanquin , Shanghai RAAS , Teva Pharmaceutical , The Medicines Company , Thermo Fisher Scientific , Tianjin SinoBiotech & Beijing Bio-Fortune , and Ventria Bioscience .
Download Sample Report @ https :// marketreportscenter . com / request-sample / 500950
Commenting on the report , an analyst from Technavio ’ s team said : “ One trend in market is establishment of plasma fractionation facilities in emerging economies by global players . Plasma fractionation in developed countries is proving very costly , so there has been a growing focus of vendors to tap the emerging economies such as the Middle East , Africa , China , and India . These geographies become a favorite due to the easy availability of skilled personnel , raw materials , cheap labor and land , a larger volume of available plasma due to large population base , and supportive government regulations . However , currently the presence of plasma fractionation facilities is very much limited to China within emerging countries , but in future , the incentives listed above should be driving the vendors to establish more facilities in these regions . For instance , in 2010 , Celestial Biologicals , an associate company of Intas Biopharmaceuticals , in collaboration with GE Healthcare started a plasma fractionation facility in India . Going forward , to benefit from the unmet demand in the emerging markets and the incentives of opening such facilities in the region , would drive global players to open number of such facilities in the region .
According to the report , one driver in market is increasing surgical procedures . The increasing surgical procedures such as hip and knee replacements will increase the risk of DVT , thereby driving the market growth . Surgeries often result in long periods of immobility , thus increasing the chances of developing DVT due to reduced blood flow . It is reported that over a million Americans undergo joint replacement surgeries every year . Individuals undergoing knee replacement and hip replacement surgeries have an increased likelihood of developing DVT . For instance , according to the CDC 2015 report , around 719,000 knee replacement surgeries and 332,000 hip replacement surgeries are performed in the US every year .